CB-13

Summary

CB-13, also known as CRA13 and SAB-378, is a cannabinoid pharmaceutical compound. This substance is a robust agonist for CB1 and CB2 receptors, yet it cannot breach the blood-brain barrier. Consequently, at lower doses, CB-13 primarily elicits peripheral effects, while indications of central effects, such as catalepsy, manifest only when administered at significantly higher doses. Notably, CB-13 has demonstrated antihyperalgesic properties in animal research, and it has advanced to the initial stages of human clinical trials.

Identifiers

IUPAC name
CAS Number	432047-72-8
PubChem CID	9799417
ChemSpider	7975182
UNII	9XRJ6055XT
ChEMBL	ChEMBL244403
CompTox Dashboard (EPA)	DTXSID60430920
Chemical and physical data
Formula	C26H24O2
Molar mass	368.476 g·mol−1

Legal Status

In October 2015, CB-13 was classified as a regulated substance in China.

North Dakota designates CB-13 as a Schedule I controlled substance.

FAQ

1. What is CB-13?

• CB-13 is a synthetic cannabinoid compound known for its activity on the endocannabinoid system, particularly as an agonist for CB1 and CB2 receptors.

2. Is CB-13 Legal?

• The legal status of CB-13 varies by country and state. It’s essential to check your local regulations. As of my last update in 2025, it was classified as a controlled substance in China and a Schedule I controlled substance in North Dakota.

3. What Are the Effects of CB-13?

• CB-13 is reported to produce both peripheral and central effects. At lower doses, it primarily exhibits peripheral effects, while higher doses may lead to central effects like catalepsy.

4. Is CB-13 Safe?

• The safety of CB-13 is a subject of ongoing research. Like other synthetic cannabinoids, it may have unpredictable and potentially harmful effects. It is crucial to consult with a healthcare professional and use it cautiously.

5. What Are the Potential Medical Uses of CB-13?

• CB-13 has demonstrated antihyperalgesic properties in animal studies, suggesting its potential as a pain management option. It has also progressed to preliminary human trials, but further research is needed.

6. How Can I Obtain CB-13 for Research or Medical Purposes?

• Access to CB-13 for research or medical purposes is subject to strict regulations. Researchers and healthcare professionals must follow local laws and regulations regarding the acquisition and use of CB-13.

7. Are There Any Known Side Effects of CB-13?

• While side effects may vary, potential side effects of CB-13 could include nausea, dizziness, and central nervous system effects at higher doses. However, more research is needed to understand its side effect profile fully.

8. Is CB-13 the Same as Cannabis or Cannabidiol (CBD)?

• No, CB-13 is a synthetic compound designed to interact with cannabinoid receptors. It differs from natural cannabis and CBD, which are plant-derived compounds with distinct properties.

9. Can CB-13 Cause Addiction?

• Like many substances that affect the endocannabinoid system, CB-13 may have addictive potential, but more research is required to determine the extent of this risk.

10. Where Can I Find More Information About CB-13?

• Stay informed through reputable sources, scientific journals, and regulatory agencies that provide updates on CB-13, its legal status, and its potential applications. Always consult with experts in the field for the latest information and guidance.

References

1. Cluny NL, Keenan CM, Duncan M, Fox A, Lutz B, Sharkey KA (September 2010). “SAB378: Unveiling a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist’s Impact on Gastrointestinal Motility and Experimental Colitis in Mice.” Published in The Journal of Pharmacology and Experimental Therapeutics, 334(3), 973–980. doi:10.1124/jpet.110.169946. PMID: 20571060. S2CID 9198992.
2. Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, et al. (August 2007). “Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A Potent, Orally Bioavailable Human CB1/CB2 Dual Agonist with Antihyperalgesic Properties and Restricted Central Nervous System Penetration.” Featured in the Journal of Medicinal Chemistry, 50(16), 3851–3856. doi:10.1021/jm070317a. PMID: 17630726.
3. Gardin A, Kucher K, Kiese B, Appel-Dingemanse S (April 2009). “CB-13: A Novel Cannabinoid Agonist – First Insights into Human Pharmacokinetics and Safety.” Presented in Drug Metabolism and Disposition, 37(4), 827–833. doi:10.1124/dmd.108.024000. PMID: 19144772. S2CID 15150118.
4. “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” [Notice on Printing and Distributing the “Measures for the Scheduling of Non-Pharmaceutical Narcotic Drugs and Psychotropic Substances”] (in Chinese). Issued by the China Food and Drug Administration on September 27, 2015. Archived from the original on October 1, 2015. Retrieved on October 1, 2015.
5. “Schedule 1” (PDF). Official document from the Sixty-eighth Legislative Assembly of North Dakota, dated January 3, 2023.